Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis

verfasst von: Su-Xia Li, Qiang-Sheng Dai, Su-Xiu Chen, Shao-Dan Zhang, Xiao-Yu Liao, Xia Deng, Hong-Bo Chi, Feng-Jie Li, Jin-Hong Zhu, Yi-Yan Jiang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Numerous epidemiological studies have been conducted to investigate the association between Xeroderma pigmentosum complementation group D (XPD) Asp312Asn (rs1799793 G > A) and Lys751Gln (rs13181 A > C) polymorphisms and bladder cancer risk; however, the conclusions remain controversial. With this in mind, we performed this meta-analysis with 11 studies including 3,797 cases and 5,094 controls for Asp312Asn and 21 studies including 6,360 cases and 7,894 controls for Lys751Gln polymorphism. We searched available literatures from PubMed, Embase, and CBM databases. Crude odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to assess the strength of the associations. Moreover, to validate biological plausibility of our findings, the effects of these two polymorphisms on XPD gene expression within three ethnicities was determine by gene expression analysis based on imputed genotypes from HapMap. Overall, the variant allele of Asp312Asn polymorphism was associated with an increased risk of bladder cancer (Asn/Asn vs. Asp/Asp: OR = 1.51, 95 % CI = 1.19–1.91; Asp/Asn vs. Asp/Asp: OR = 1.23, 95 % CI = 1.12–1.35; recessive model: OR = 1.33, 95 % CI = 1.10–1.61; dominant model: OR = 1.32, 95 % CI = 1.14–1.52; and allele comparing: OR = 1.26, 95 % CI = 1.11–1.42). We found the Lys751Gln was associated with increased bladder cancer risk only under the recessive model (OR = 1.14, 95 % CI = 1.01–1.29). Stratification analyses demonstrated an increased risk for Asians and hospital-based studies under all genetic models while only under the dominant model for Caucasians as to the Asp312Asn polymorphism and for Caucasians under the recessive model as to the Lys751Gln polymorphism. We also found the Asp312Asn polymorphism can significantly influence mRNA expression levels among Asians and Caucasians, and the Lys751Gln polymorphism has a similar effect for Caucasians. Despite some limitations, this meta-analysis suggests that polymorphisms in XPD gene may contribute to bladder cancer susceptibility. These findings need further validation by large well-designed prospective studies.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed
3.
Zurück zum Zitat Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.PubMedCrossRef Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.PubMedCrossRef
4.
Zurück zum Zitat Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene. 2004;23:6500–23.PubMedCrossRef Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene. 2004;23:6500–23.PubMedCrossRef
5.
Zurück zum Zitat Bosetti C, Pira E, La Vecchia C. Bladder cancer risk in painters: a review of the epidemiological evidence, 1989–2004. Cancer Causes Control. 2005;16:997–1008.PubMedCrossRef Bosetti C, Pira E, La Vecchia C. Bladder cancer risk in painters: a review of the epidemiological evidence, 1989–2004. Cancer Causes Control. 2005;16:997–1008.PubMedCrossRef
6.
Zurück zum Zitat Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.PubMedCrossRef Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.PubMedCrossRef
7.
Zurück zum Zitat Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
8.
Zurück zum Zitat Lamerdin JE, Stilwagen SA, Ramirez MH, Stubbs L, Carrano AV. Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Genomics. 1996;34:399–409.PubMedCrossRef Lamerdin JE, Stilwagen SA, Ramirez MH, Stubbs L, Carrano AV. Sequence analysis of the ERCC2 gene regions in human, mouse, and hamster reveals three linked genes. Genomics. 1996;34:399–409.PubMedCrossRef
9.
Zurück zum Zitat Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef
10.
Zurück zum Zitat Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1004–11.PubMed Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1004–11.PubMed
11.
Zurück zum Zitat Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case–control study in northern Italy. Cancer Epidemiol Biomarkers Prev. 2003;12:1234–40.PubMed Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case–control study in northern Italy. Cancer Epidemiol Biomarkers Prev. 2003;12:1234–40.PubMed
12.
Zurück zum Zitat Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef
13.
Zurück zum Zitat Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef
14.
Zurück zum Zitat Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14:2569–78.PubMedCrossRef Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14:2569–78.PubMedCrossRef
15.
Zurück zum Zitat Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, et al. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:878–84.PubMedCrossRef Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, et al. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:878–84.PubMedCrossRef
16.
Zurück zum Zitat Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030–7.PubMedCrossRef Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030–7.PubMedCrossRef
17.
Zurück zum Zitat Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef
18.
Zurück zum Zitat Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.PubMedCrossRef Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.PubMedCrossRef
19.
Zurück zum Zitat Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell–cycle–control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell–cycle–control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Shao J, Gu M, Xu Z, Hu Q, Qian L. Polymorphisms of the DNA gene XPD and risk of bladder cancer in a Southeastern Chinese population. Cancer Genet Cytogenet. 2007;177:30–6.PubMedCrossRef Shao J, Gu M, Xu Z, Hu Q, Qian L. Polymorphisms of the DNA gene XPD and risk of bladder cancer in a Southeastern Chinese population. Cancer Genet Cytogenet. 2007;177:30–6.PubMedCrossRef
21.
Zurück zum Zitat Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, et al. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered. 2008;65:105–18.PubMedCrossRef Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, et al. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered. 2008;65:105–18.PubMedCrossRef
22.
Zurück zum Zitat Covolo L, Placidi D, Gelatti U, Carta A, Scotto Di Carlo A, et al. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case–control study. Eur J Epidemiol. 2008;23:355–62.PubMedCrossRef Covolo L, Placidi D, Gelatti U, Carta A, Scotto Di Carlo A, et al. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case–control study. Eur J Epidemiol. 2008;23:355–62.PubMedCrossRef
23.
Zurück zum Zitat Fontana L, Bosviel R, Delort L, Guy L, Chalabi N, et al. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res. 2008;28:1853–6.PubMed Fontana L, Bosviel R, Delort L, Guy L, Chalabi N, et al. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res. 2008;28:1853–6.PubMed
24.
Zurück zum Zitat Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, et al. Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res. 2009;29:3903–7.PubMed Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, et al. Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res. 2009;29:3903–7.PubMed
25.
Zurück zum Zitat Gangwar R, Ahirwar D, Mandhani A, Mittal RD. Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India. Urology. 2009;73:675–80.PubMedCrossRef Gangwar R, Ahirwar D, Mandhani A, Mittal RD. Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India. Urology. 2009;73:675–80.PubMedCrossRef
26.
Zurück zum Zitat Narter KF, Ergen A, Agachan B, Gormus U, Timirci O, et al. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res. 2009;29:1389–93.PubMed Narter KF, Ergen A, Agachan B, Gormus U, Timirci O, et al. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res. 2009;29:1389–93.PubMed
27.
Zurück zum Zitat Gao W, Romkes M, Zhong S, Nukui T, Persad RA, et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep. 2010;24:257–62.PubMedCentralPubMed Gao W, Romkes M, Zhong S, Nukui T, Persad RA, et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep. 2010;24:257–62.PubMedCentralPubMed
28.
Zurück zum Zitat Rouissi K, Bahria IB, Bougatef K, Marrakchi R, Stambouli N, et al. The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer. 2011;11:101.PubMedCentralPubMedCrossRef Rouissi K, Bahria IB, Bougatef K, Marrakchi R, Stambouli N, et al. The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer. 2011;11:101.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Wang YH, Yeh SD, Shen KH, Shen CH, Tung MC, et al. Association of hOGG1 and XPD polymorphisms with urothelial carcinoma in Taiwan. Anticancer Res. 2011;31:3939–44.PubMed Wang YH, Yeh SD, Shen KH, Shen CH, Tung MC, et al. Association of hOGG1 and XPD polymorphisms with urothelial carcinoma in Taiwan. Anticancer Res. 2011;31:3939–44.PubMed
30.
Zurück zum Zitat Mittal RD, Mandal RK. Genetic variation in nucleotide excision repair pathway genes influence prostate and bladder cancer susceptibility in North Indian population. Indian J Hum Genet. 2012;18:47–55.PubMedCentralPubMedCrossRef Mittal RD, Mandal RK. Genetic variation in nucleotide excision repair pathway genes influence prostate and bladder cancer susceptibility in North Indian population. Indian J Hum Genet. 2012;18:47–55.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, et al. Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol. 2012;31:199–210.PubMedCentralPubMedCrossRef Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, et al. Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol. 2012;31:199–210.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007;28:2160–5.PubMedCrossRef Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007;28:2160–5.PubMedCrossRef
33.
Zurück zum Zitat Andrew AS, Mason RA, Kelsey KT, Schned AR, Marsit CJ, et al. DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicol Lett. 2009;187:10–4.PubMedCentralPubMedCrossRef Andrew AS, Mason RA, Kelsey KT, Schned AR, Marsit CJ, et al. DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicol Lett. 2009;187:10–4.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, et al. ERCC1 haplotypes modify bladder cancer risk: a case–control study. DNA Repair (Amst). 2010;9:191–200.PubMedCrossRef Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, et al. ERCC1 haplotypes modify bladder cancer risk: a case–control study. DNA Repair (Amst). 2010;9:191–200.PubMedCrossRef
35.
Zurück zum Zitat Rouissi K, Ouerhani S, Hamrita B, Bougatef K, Marrakchi R, et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol Oncol Res. 2011;17:879–86.PubMedCrossRef Rouissi K, Ouerhani S, Hamrita B, Bougatef K, Marrakchi R, et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol Oncol Res. 2011;17:879–86.PubMedCrossRef
36.
Zurück zum Zitat He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44.PubMedCrossRef He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44.PubMedCrossRef
37.
Zurück zum Zitat He J, Shi TY, Zhu ML, Wang MY, Li QX, et al. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis. Int J Cancer. 2013;133:1765–75.PubMedCrossRef He J, Shi TY, Zhu ML, Wang MY, Li QX, et al. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis. Int J Cancer. 2013;133:1765–75.PubMedCrossRef
38.
Zurück zum Zitat Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM, et al. Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. Carcinogenesis. 2013;34:770–8.PubMedCrossRef Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM, et al. Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. Carcinogenesis. 2013;34:770–8.PubMedCrossRef
39.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
40.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
42.
Zurück zum Zitat Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698–705.PubMedCrossRef Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698–705.PubMedCrossRef
43.
Zurück zum Zitat Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301–9.PubMedCrossRef Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301–9.PubMedCrossRef
44.
Zurück zum Zitat Weber CA, Salazar EP, Stewart SA, Thompson LH. Molecular cloning and biological characterization of a human gene, ERCC2, that corrects the nucleotide excision repair defect in CHO UV5 cells. Mol Cell Biol. 1988;8:1137–46.PubMedCentralPubMed Weber CA, Salazar EP, Stewart SA, Thompson LH. Molecular cloning and biological characterization of a human gene, ERCC2, that corrects the nucleotide excision repair defect in CHO UV5 cells. Mol Cell Biol. 1988;8:1137–46.PubMedCentralPubMed
45.
Zurück zum Zitat Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10:1219–32.PubMedCrossRef Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996;10:1219–32.PubMedCrossRef
46.
Zurück zum Zitat Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15:15–23.PubMedCrossRef Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15:15–23.PubMedCrossRef
47.
Zurück zum Zitat Dai QS, Hua RX, Zeng RF, Long JT, Peng ZW. XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis. Tumour Biol. 2013. doi:10.1007/s13277-013-1062-y. Dai QS, Hua RX, Zeng RF, Long JT, Peng ZW. XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1062-y.
48.
Zurück zum Zitat Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–8.PubMed Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–8.PubMed
Metadaten
Titel
Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis
verfasst von
Su-Xia Li
Qiang-Sheng Dai
Su-Xiu Chen
Shao-Dan Zhang
Xiao-Yu Liao
Xia Deng
Hong-Bo Chi
Feng-Jie Li
Jin-Hong Zhu
Yi-Yan Jiang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1519-z

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.